Leflunomide in treatment of RA patents preliminary estimation of therapeutical efficiency and side effects
More details
Hide details
Online publication date: 2006-02-15
Reumatologia 2006;44(1):19–25
In the preliminary estimation there were studied efficiency and safety of therapy leflunomid in patients with RA. The drug was given p. o. to a group of 158 patients (150 females and 8 males) for 3 days 100 mg/24 h, and then again 20 mg/24 h. The age of patients varied between 19-78 (average age was 55 years), with average duration time of the disease 10 years and 2 months. All of the patients were previously unsuccessfully treated with other DMARDS. All of the patients had high activity of disease estimated by DAS 28 ≥5.1 61.4% of patients were treated with long-term glicocorticosteroids. Time of trial was scheduled for 6 months. The therapeutical effect was initially estimated on the basis of a group of 43 patients who took the medicine for 91-120 days. Good and average therapeutical efficiency of treatment was observed in 76.73% of patients. Efficiency was expressed by lowering DAS 28 by 0.6-1.2 in a group of 11.62% of patients and 1.2 in a group of 65.11% of patients. In a group of 3.79% of patients the treatment was stopped because of complete lack of therapeutical effect. Frequency of side effects was initially estimated in a group of 158 patients. Treatment was interrupted in the group of 8.86% of patients because of such side effects as: diarrheas, elevation of transaminazes, leukopenia and trombocytopenia, skin changes and dizziness. Observations are continued. Preliminary results of observations allow for positive evaluation of treatment with leflunomid in RA patients.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.